PRESENTATION

Q3 2026 — Results presentation

Q3 2026PDF · 27 pages4.9 MB
1

-- 1 of 27 --

3rd Quarter 2026
Earnings Call
October 13, 2026

-- 2 of 27 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased
scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from
the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in
the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and
other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of
new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 27 --

Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab
A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc.
relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences
Immunology REMICADE marketing partner with Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration
with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.
Other
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with
Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion
agreement with Nippon Shinyaku in Japan
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 27 --

CEO Remarks
Sales performance and earnings review
Capital allocation and guidance update
Q&A
Agenda
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Ryan Koors
Vice President,
Investor Relations
Tom Cavanaugh
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech
1
2
3
4

-- 5 of 27 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 27 --

Q3 Earnings Summary
6.0%
operational sales
growth 1,2
Six key businesses driving growth
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Includes an approximate (420) basis point headwind from STELARA
Cardiovascular
Oncology 	Immunology 	Neuroscience
Vision	Surgery
7

-- 7 of 27 --

29 Platforms / Products > 1 Billion in Annual Sales
Innovative Medicine (16) 	MedTech (13)
Electrophysiology 	Contact
Lenses
Surgical
Vision
Biosurgery
Trauma
Shockwave
Abiomed
Knees
Hips
Spine	Energy
Endocutters
Wound
Closure
8

-- 8 of 27 --

Innovative Medicine: 7.9% operational sales growth 1,2
Oncology 	Neuroscience	Immunology
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Includes an approximate (690) basis point headwind from STELARA
9

-- 9 of 27 --

MedTech: 2.5% operational sales growth1
Cardiovascular 	Surgery 	Vision
VARIPULSE 	Platform 	Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
Impella® Heart
Pump Technology
OTTAVA 	Robotic
Surgical System
ETHICON 	4000 Surgical Stapler
with 3D Stapling Technology
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Includes existing products and planned future launches
SURGIFLO 	Hemostatic
Matrix Kit
STRATAFIX 	Knotless
Tissue Control Devices
10

-- 10 of 27 --

OTTAVA 	U.S. FDA market authorization opens a new
category in surgical robotics
De Novo authorization spans 10 general surgery procedures, including:
• 	Gastric bypass
• 	Gastric sleeve
Occupies 30–50% less space than boom- and cart-mounted systems
Connects to the Polyphonic 	open digital ecosystem for data-driven insights
First commercial customer signed
Inguinal hernia trial in progress
The world’s first table-integrated soft tissue robotic system —
four arms built into a standard surgical table
Surgery
OTTAVA TM Robotic Surgical System
• 	Cholecystectomy
• 	Hiatal hernia repair
11

-- 11 of 27 --

MedTech: 2.5% operational sales growth1
Cardiovascular 	Surgery 	Vision
VARIPULSE 	Platform 	Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
Impella® Heart
Pump Technology
OTTAVA 	Robotic
Surgical System
ETHICON 	4000 Surgical Stapler
with 3D Stapling Technology
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Includes existing products and planned future launches
SURGIFLO 	Hemostatic
Matrix Kit
STRATAFIX 	Knotless
Tissue Control Devices
12

-- 12 of 27 --

Johnson & Johnson is built
for durable growth
13

-- 13 of 27 --

Ryan Koors
Vice President,
Investor Relations

-- 14 of 27 --

Regional sales results 	Q3 2026 	Q3 2025
% Change
Reported 	Operational 1
U.S. 	$15.0 	$13.7 	9.1% 	9.1%
Europe 	5.4 	5.4 	(0.6) 	1.0
Western Hemisphere
(ex U.S.) 1.4 	1.2 	12.5 	8.0
Asia-Pacific, Africa 	3.7 	3.6 	1.0 	1.0
International 	10.4 	10.3 	1.5 	1.8
Worldwide (WW) 	$25.4 	$24.0 	5.9% 	6.0%
Dollars in billions
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded
3rd Quarter 2026 sales
15

-- 15 of 27 --

$25.4 $24.0
$6.34 	$6.8
(7.5)%; (6.8)% 1
$2.594 	$2.80
Dollars in billions, except EPS
Reported %; Operational %1
Sales
Adjusted earnings2 	Adjusted EPS 2
5.9%; 6.0% 1
GAAP earnings
(6.8)%
Q3 2026 	Q3 2025
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
3 Includes the impact of a one-time special charge related to the proposed talc litigation resolution, as well as expenses related to the acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines
4 Includes expenses related to the acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines
3rd Quarter 2026 financial highlights
GAAP EPS
16
Q3 2026 	Q3 2025 	Q3 2026 	Q3 2025
Q3 2026 	Q3 2025 	Q3 2026 	Q3 2025
(95.9)% 	(95.8)%
$0.23
$5.2
$0.093
$2.12
Includes one-
time special
charges
Includes one-
time special
charges

-- 16 of 27 --

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded
Other
$2,560
Neuroscience
$2,375
Oncology
$7,602
Immunology
$4,221
■ Reported growth 	■ Operational growth1
$16,757
7.7%, 7.9%
WW sales $MM
Key drivers of operational performance 1
Oncology
• 	DARZALEX increase primarily driven by strong share gains and market growth
• 	CARVYKTI increase driven by share gains and continued site expansion
• 	TECVAYLI growth driven by share gains following U.S. TECVAYLI + DARZALEX
FASPRO approval
• 	TALVEY growth driven by share gains from expansion in the community setting
• 	RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains
• 	ERLEADA increase driven by continued share gains in mCSPC and market growth,
partially offset by unfavorable patient mix
• 	IMBRUVICA decrease driven by share loss due to continued competitive pressure
and unfavorable patient mix
• 	OTHER ONCOLOGY growth driven by INLEXZO U.S. launch uptake
Immunology
• 	TREMFYA growth due to share gains across all indications with significant IBD launch
momentum and market growth
• 	SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar
competition, and unfavorable patient mix, partially offset by market growth
• 	STELARA decline driven by the impact of biosimilar competition and increasing
adoption of novel classes
• 	OTHER IMMUNOLOGY increase driven by IMAAVY and ICOTYDE launch uptake in
the U.S.
Neuroscience
• 	SPRAVATO growth driven by continued share gains, supported by increased patient
demand due to strong physician adoption
• 	CAPLYTA growth driven by strong continued momentum in the aMDD launch and
continued demand across bipolar disorder and schizophrenia
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily
driven by favorable patient mix and inventory dynamics, partially offset by share loss
Other
• 	UPTRAVI flat due to unfavorable patient mix, partially offset by market growth
• 	OPSUMIT/OPSYNVI decrease driven by lower demand following U.S. generic
entrants
• 	PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA decrease driven by declines in
share and market, partially offset by favorable patient mix
• 	XARELTO increase driven by favorable patient mix, partially offset by continued
share erosion
Adjusted operational sales 2 : WW 8.0%, U.S. 11.1%, Int’l 3.2%
Innovative Medicine highlights – 3rd quarter 2026
Reported: 	WW 7.7%, U.S. 11.1%, Int’l 2.4%
Operational 1: 	WW 7.9%, U.S. 11.1%, Int’l 3.0%
1.3%, 1.4%
16.4%, 16.7%
(9.9)%, (9.6)%
Strong operational growth 1 of 7.9% driven primarily by new product launches
17.3%, 17.6%
17
Stelara impacted results 1 by ~(690) basis points

-- 17 of 27 --

Surgery
$2,528
Orthopaedics
$2,345
Vision
$1,461
Cardiovascular
$2,307
■ Reported growth 	■ Operational growth 1
$8,642
2.5%, 2.5%
WW sales $MM
Modest operational growth 1 of 2.5% driven primarily by commercial execution and innovation
Reported: 	WW 2.5%, U.S. 4.8%, Int’l 0.1%
Operational 1: 	WW 2.5%, U.S. 4.8%, Int’l 0.1%
4.3%, 4.1%
4.4%, 5.1%
(0.6)%, (1.0)%
3.2%, 3.4%
MedTech highlights – 3rd quarter 2026
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded 	18
Key drivers of operational performance 1
Cardiovascular
• 	Electrophysiology: Increase driven by procedure growth, commercial execution, and
new product performance (VARIPULSE, TRUPULSE, CRYSTAL, DUAL ENERGY
STSF), partially offset by competitive pressures in PFA and OUS inventory dynamics
• 	Abiomed: Decline driven by lower patient volumes, partially offset by sustained
adoption of Impella 5.5
• 	Shockwave: Double-digit growth driven by continued strong adoption of Coronary
and Peripheral portfolios and new product launches (AERO C2)
Surgery
Surgery decline driven by VBP in China, impact of the surgery transformation
program, and disruptions in the Middle East
• 	Advanced:
• 	Biosurgery: ~ +3% growth driven by continued strength of the portfolio and
commercial execution, partially offset by the impact of the surgery
transformation program and VBP in China
• 	Endocutters: ~ -4% due to VBP in China, impact of the surgery transformation
program, and competitive pressures, partially offset by new products
• 	Energy: ~ 0% driven by impact of the surgery transformation program, VBP in
China, and competitive pressures, partially offset by new product launches
• 	General: Decrease primarily driven by VBP in China, partially offset by technology
penetration and upgrades within our differentiated Wound Closure portfolio (Barbed
& PLUS Sutures) and market expansion
Vision
• 	Contact Lenses/Other: Increase driven by strong performance of the ACUVUE
OASYS 1-Day family of products including recent launches and strategic price actions,
partially offset by inventory dynamics
• 	Surgical: Growth driven by strength of recent product innovations, robust demand for
premium IOLs, and strong commercial execution, partially offset by disruptions in the
Middle East
Orthopaedics
• 	Hips: Increase driven by new product launches (EMPHASYS)
• 	Knees: Increase driven by strength of the ATTUNE portfolio, in part driven by pull-
through related to the VELYS Robotic assisted solutions
• 	Trauma: Growth driven by recently launched products (VOLT) and commercial
execution, partially offset by OUS inventory dynamics
• 	Spine, Sports & Other: ~ Flat due to new product innovations, partially offset by
competitive pressures and inventory dynamics
Adjusted operational sales 2 : WW 2.5%, U.S. 4.8%, Int’l 0.1%

-- 18 of 27 --

2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$25,399 	100.0 	$23,993 	100.0 	5.9
Cost of products sold 	8,097 	31.9 	7,303 	30.4 	10.9
Gross Profit 	17,302 	68.1 	16,690 	69.6 	3.7
Selling, marketing and administrative expenses 	6,285 	24.7 	5,922 	24.7 	6.1
Research and development expense 	4,652 	18.3 	3,672 	15.3 	26.7
In-process research and development impairments 	339 	1.4 	- 	-
Interest (income) expense, net 	31 	0.1 	18 	0.1
Other (income) expense, net 	5,780 	22.8 	(478) 	(2.0)
Restructuring 	181 	0.7 	63 	0.3
Earnings before provision for taxes on income 	34 	0.1 	7,493 	31.2 	(99.5)
(Benefit from)/Provision for taxes on income 	(176) 	(0.7) 	2,341 	9.7 	(107.5)
Net Earnings 	$210 	0.8 	$5,152 	21.5 	(95.9)
Net earnings per share (Diluted) 	$0.09 	$2.12 	(95.8)
Average shares outstanding (Diluted) 	2,448.6 	2,428.6
Effective tax rate 	(517.6)% 	31.2%
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income 	$7,672 	30.2 	$8,436 	35.2 	(9.1)
Net earnings 	$6,339 	25.0 	$6,801 	28.3 	(6.8)
Net earnings per share (Diluted) 	$2.59 	$2.80 	(7.5)
Effective tax rate 	17.4% 	19.4%
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
(Unaudited; Dollars and shares in millions except per share figures)
19
3 rd Quarter 2026
Condensed consolidated statement of earnings

-- 19 of 27 --

Innovative Medicine
(2026 includes the impact of M&A transactions: Firefly Bio, Inc. & Sail Biomedicines)
2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$16,757 	100.0 	$15,563 	100.0 	7.7
Cost of products sold 	3,740 	22.3 	3,093 	19.9 	20.9
Gross Profit 	$13,017 	77.7 	$12,470 	80.1 	4.4
Selling, marketing and administrative expenses 	3,035 	18.1 	2,869 	18.4 	5.8
Research and development expense 1 	3,888 	23.2 	2,944 	18.9 	32.1
Other segment items 2,3 	165 	1.0 	(238) 	(1.5)
Adjusted segment income before tax 4 	$5,929 	35.4 	$6,895 	44.3 	(14.0)
(Unaudited; Dollars in millions)
Adjusted earnings before provision for taxes on income by segment
20
MedTech 2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,642 	100.0 	$8,430 	100.0 	2.5
Cost of products sold 	3,100 	35.9 	3,119 	37.0 	(0.6)
Gross Profit 	$5,542 	64.1 	$5,311 	63.0 	4.3
Selling, marketing and administrative expenses 	2,976 	34.4 	2,801 	33.2 	6.2
Research and development expense 	759 	8.8 	728 	8.6 	4.3
Other segment items 2 	(173) 	(2.0) 	15 	0.2
Adjusted segment income before tax 4 	$1,980 	22.9 	$1,767 	21.0 	12.1
Enterprise
(2026 includes the impact of M&A transactions: Firefly Bio, Inc. & Sail Biomedicines)
2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Adjusted income before tax 1,3,4 	$7,672 	30.2 	$8,436 	35.2 	(9.1)
3 rd Quarter 2026
1 Includes expenses related to the acquisition of Firefly Bio, Inc.
2 Includes other Income and Expense
3 Includes transaction costs related to the strategic collaboration with Sail Biomedicines
4 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website

-- 20 of 27 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 21 of 27 --

Capital allocation
Organic growth business needs
Free cash flow 1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Dollars in billions 	Q3 2026
Cash and marketable
securities $17
Debt 	($45)
Net debt 	($28)
Free cash flow1,2 ~$15
Q3 2026:
$4.7B invested in R&D
$11.8B year-to-date
$3.2B in dividends paid
to shareholders
$9.6B year-to-date
Note: Values may be rounded
1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 Estimated as of October 13, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
Note: Values may be rounded
Capital allocation strategy
22

-- 22 of 27 --

Operational2 sales guidance of 6.9% and adjusted operational EPS 2,4 at 2.0% (midpoints)
October 2026 	July 29, 2026 	Comments
Adjusted operational sales 1,2 	6.4% - 6.8% 	6.2% - 6.8% Tightening range;
Increasing midpoint to 6.6%
Operational sales 2 	$100.5B - $100.9B
6.7% - 7.1%
$100.3B - $100.9B
6.5% - 7.1%
Tightening range;
Increasing midpoint by $0.1B to 6.9%
Estimated reported sales 3 	$101.0B - $101.4B
7.2% - 7.6%
$100.8B - $101.4B
7.0% - 7.6%
Tightening range;
Increasing midpoint by $0.1B to 7.4%
Maintaining FX impact of $0.5B or 0.5%
Adjusted pre-tax
operating margin4,5 	Decrease of approximately 60 bps 	Decrease of approximately 75 bps 	Improving
Net other income 4 	$0.8 - $1.0 billion 	$1.0 - $1.2 billion 	Decreasing
Net interest expense / (income) 	$150 - $200 million 	$250 - $350 million 	Decreasing and tightening range
Effective tax rate 4 	17.0% - 17.5% 	17.0% - 18.0% 	Decreasing and tightening range
Adjusted EPS (operational) 2,4 	$10.95 - $11.05
1.5% - 2.4%
$10.86 - $11.01
0.7% - 2.1%
Increasing and tightening range;
Increasing midpoint by $0.06 to 2.0%
Adjusted EPS (reported) 3,4 	$11.05 - $11.15
2.4% - 3.3%
$10.96 - $11.11
1.6% - 3.0%
Increasing and tightening range;
Increasing midpoint by $0.06 to 2.9%
Maintaining FX impact of $0.10 or 0.9%
2026 P&L guidance
1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15
Note: Values may be rounded 	23

-- 23 of 27 --

Innovative Medicine
2026 milestones1 driving long-term value creation
MedTech
24
TECVAYLI + TALVEY in RRMM
Pasritamig in prostate cancer
JNJ-6143 in prostate cancer
INLEXZO in HR NMIBC
ICOTYDE in PsA
CAPLYTA in bipolar mania
TREMFYA in PsA SD
nipocalimab in wAIHA and SLE
Dual Energy THERMOCOOL STSF
C2 Aero Catheters
VARIPULSE Pro
OTTAVA
ETHICON 4000
TECNIS PureSee IOL
MONARCH Urology
VOLT suite of products
1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches
RRMM: Relapsed/refractory multiple myeloma; HR NMIBC: High-risk non-muscle invasive bladder cancer; PsA: Psoriatic arthritis; PsA SD: Psoriatic arthritis structural damage; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; STSF: SMARTTOUCH Surround Flow; IOL:
Intraocular lens

-- 24 of 27 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Ryan Koors
Vice President,
Investor Relations
Tom Cavanaugh
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 25 of 27 --

Slide footer goes here if required 	26

-- 26 of 27 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
 	US TREMFYA (guselkumab) 	 	US IMAAVY (nipocalimab) 	US ERLEADA (apalutamide) 	ICOTYDE (icotrokinra) 	ERLEADA (apalutamide) 	 JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis Structural
Damage (APEX)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
EU Localized Prostate Cancer (ATLAS) 	Psoriasis (ICONIC-ASCEND) 	Localized Prostate Cancer (ATLAS) 	Ulcerative Colitis (DUET-UC)
 	US ICOTYDE (icotrokinra) 	US CAPLYTA (lumateperone) 	US ERLEADA (apalutamide) 	 	ICOTYDE (icotrokinra) 	 ERLEADA (apalutamide) 	 JNJ-4804 Co-antibody Therapy
 	EU Psoriasis (ICONIC) 	Bipolar Mania 	EU High Risk Prostate Cancer (PROTEUS) 	Psoriasis (ICONIC-ADVANCE
1&2 Update)
High Risk Prostate Cancer (PROTEUS) 	Crohn's Disease (DUET-CD)
 	US IMAAVY (nipocalimab) 	US bleximenib 	icotrokinra 	 TALVEY (talquetamab) 	 JNJ-4804 Co-antibody Therapy
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Relapsed Refractory Acute Myeloid
Leukemia (cAMeLot-1)
Psoriatic Arthritis (ICONIC-
PsA)
Relapsed Refractory Multiple Myeloma
A-CD38 Naïve (MonumenTAL-3)
Psoriatic Arthritis (AFFINITY)
AKEEGA (niraparib/abiraterone) 	 	US TALVEY (talquetamab) 	 	ICOTYDE (icotrokinra) 	TALVEY (talquetamab) 	 nipocalimab
EU M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)
 	EU Relapsed Refractory Multiple Myeloma
A-CD38 Naïve (MonumenTAL-3)
Psoriasis (ICONIC-TOTAL
Update)
Relapsed Refractory Multiple Myeloma
CD38 exposed (MonumenTAL-6)
Systemic Lupus Erythematosus
(JASMINE)
 	US DARZALEX (daratumumab) 	 	US TALVEY (talquetamab) 	 	CAPLYTA (lumateperone) 	 TECVAYLI (teclistamab) 	bleximenib
Frontline multiple myeloma
transplant ineligible (CEPHEUS)
 	EU Relapsed Refractory Multiple Myeloma
CD38 exposed (MonumenTAL-6)
Bipolar Mania (ITI-007-451) 	Relapsed Refractory Multiple Myeloma
CD38 exposed (MajesTEC-9)
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)
 	US TECVAYLI (teclistamab) 	 	US TECVAYLI (teclistamab) 	CAPLYTA (lumateperone)
INLEXZO (gemcitabine intravesical
delivery system) 	pasritamig + JNJ-9401
 	EU Multiple Myeloma 1-3PLs
(MajesTEC-3)
 	EU Relapsed Refractory Multiple Myeloma
CD38 exposed (MajesTEC-9)
Bipolar Mania (ITI-007-452) 	High Risk Non Muscle Invasive Bladder
Cancer BCG Experienced (SunRISe-5)
Prostate Cancer (PCR1001)
TECVAYLI (teclistamab) 	TECVAYLI (teclistamab) 	 	IMAAVY (nipocalimab) 	JNJ-6143 (HLD-0915)
EU Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)
 	EU Multiple Myeloma 1-3PLs (MajesTEC-3) 	Warm Autoimmune Hemolytic
Anemia (ENERGY)
Prostate Cancer (FIH Update)
US RYBREVANT (amivantamab) 	 	US RYBREVANT (amivantamab)
Head and Neck Cancer
(ORIGAMI-4)
Head and Neck Cancer (ORIGAMI-4)
US
INLEXZO (gemcitabine intravesical
delivery system)
EU High Risk Non Muscle Invasive Bladder
Cancer BCG Experienced (SunRISe-5)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2026*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and
assets and does not guarantee continued investment. This information is as of October 13, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

-- 27 of 27 --